TobeyJMacDonaldMD

Pediatric Hematology & Oncology • Atlanta, GA

Pediatric Neuro-Oncology

Director and Aflac Chair of Pediatric Neuro-Oncology, Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta and Emory University, Professor of Pediatrics, Emory University School of Medicine

Join to view full profile

Dr. MacDonald is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. MacDonald's full profile

Already have an account?

Office
2015 Uppergate Drive, 4th floor
Aflac Cancer & Blood Disorders Center
Atlanta, GA 30322
Phone+1 404-727-4455

Fax+1 404-727-4455

Summary

Dr. Tobey MacDonald is a pediatric hematologist/oncologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Children's Healthcare of Atlanta, Emory University Hospital, and Children's Healthcare of Atlanta. He received his medical degree from Weill Cornell Medical College of Cornell University and has been in practice 26 years. He specializes in pediatric neuro-oncology.

Education & Training

Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1994 - 1997
Children's Hospital Los AngelesResidency, Pediatrics, 1991 - 1994
Weill Cornell MedicineClass of 1991
Cornell UniversityBA, Biology, 1983 - 1987

Certifications & Licensure

CA State Medical License 1992 - Present
GA State Medical License 2009 - 2025
DC State Medical License 1998 - 2010
VA State Medical License 1998 - 2010
MD State Medical License 1998 - 2009
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Top Doctors- Pediatric Hematology Oncology US News & World Report

Clinical Trials

Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children Start of enrollment: 2001 Mar 01
Completed
Cilengitide in Treating Children With Refractory Primary Brain Tumors Start of enrollment: 2003 Jul 01
Completed
Phase 1
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Start of enrollment: 2011 Sep 01
Terminated
Phase 2
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Start of enrollment: 2010 Aug 01
Completed
Phase 2
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor Start of enrollment: 2011 Aug 01
Completed
Phase 2
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) Start of enrollment: 2013 May 06
Completed
Phase 2
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma Start of enrollment: 2017 Apr 04
Terminated
Early Phase 1
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Start of enrollment: 2019 Oct 02
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

170 citations
An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
Michelle B. Mintz, Rebecca Sowers, Kevin M. Brown, Sara C. Hilmer, BethAnne Mazza
Cancer Research. 2005-03-01
316 citations
Clonal selection drives genetic divergence of metastatic medulloblastoma
Xiaochong Wu, Paul A. Northcott, Adrian M. Dubuc, Adam J. Dupuy, David Shih
Nature. 2012-02-23
71 citations
Medulloblastoma subgroups remain stable across primary and metastatic compartments
Xin Wang, Adrian M. Dubuc, Vijay Ramaswamy, Stephen C. Mack, Deena M.A. Gendoo
Acta Neuropathologica. 2015-01-21

Journal Articles

White Matter Network Topology Relates to Cognitive Flexibility and Cumulative Neurological Risk in Adult Survivors of Pediatric Brain Tumors
Tobey MacDonald, MD, ScienceDirect

Press Mentions

Georgia State University Researcher Awarded $3 Million to Study Brain Cancer SurvivorsDecember 8th, 2022
Breaching the Blood-Brain Barrier to Deliver Precious PayloadsMay 7th, 2021
Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory UniversityOctober 1st, 2020
Join now to see all

Grant Support

The Role Of Pdgfr In Medulloblastoma ProgressionNational Cancer Institute2010
The Role Of Pdgfr In Medulloblastoma ProgressionNational Cancer Institute2006–2009
Phase II Study Of Bevacizumab PLUS Irinotecan (CAMPTORSAR) In Children With RecrNational Center For Research Resources2007–2008
Pbtc 007 V10b- A Phase I/II Trial Of Zd 1839 (IRESSA)National Center For Research Resources2006–2008
Pbtc016: A Phase I, Molecular Biology And Phase II Study Of Lapatinib (Gw5720aNational Center For Research Resources2006
Pbtc-017: Phase I Study Of Cloretazine (VNP40101M) In Children With Recurrent,National Center For Research Resources2006
Regulation- Medulloblastoma Growth By Alpha-V IntegrinsNational Cancer Institute2002–2006
Phase I Trial Of SCH 66336 In Ped Patient W/ Refractory Or Recurrent Brain TumorNational Center For Research Resources2005
Pbtc009 - Phase I Trial Of Gliadel And O6-BenzylguanineNational Center For Research Resources2005
Pbtc-012: Phase I Study Of Cilengiude (Emd 121974) In Child W Brain TumorsNational Center For Research Resources2005
Pbtc-006: A Phase I/II Trial Of STI571 In ChildrenNational Center For Research Resources2005
Pbtc 005 - Phase I Trial Of Temozolomide &06 Benzylguanine In Pediatric PatientNational Center For Research Resources2005
Pbtc 007 V1.0b- A Phase I/II Trial Of Zd 1839 (IRESSA)National Center For Research Resources2004
Pbtc 005v1.1 Phase I Trial Of Temozolomide And O6-BenzylguanineNational Center For Research Resources2004
Pbtc 003-A Phase I Trial Of Escalating Oral Dose Of SCH66336 In PediatricNational Center For Research Resources2004
A Phase I Study Of Cilengitide (Emd 121974) In Pediatric Patients With RefractorNational Center For Research Resources2004